Molecular Assemblies, Inc. is thrilled to announce a major funding milestone with the successful raise of $83 million, marking a pivotal moment in the evolution of DNA technology and innovation. Based in San Diego, this breakthrough capital injection will further fuel our mission to revolutionize the way DNA is synthesized using our groundbreaking Fully Enzymatic Synthesis (FES™) process. As a private life sciences company, we are dedicated to developing cutting-edge enzymatic DNA synthesis technology that mirrors nature’s own method of creating DNA—producing long, high-quality, sequence-specific strands in a manner that is both cost-effective and environmentally sustainable. With this new funding, Molecular Assemblies is well-positioned to accelerate research and development efforts, scaling our patented FES technology to meet growing global demands across diverse industries.
The infusion of capital will be strategically allocated towards enhancing our production capabilities and advancing collaborative partnerships with key stakeholders in industrial synthetic biology, precision medicine, and emerging fields such as nanomachines and bio-based electronics. Our commitment to innovation and sustainability drives us to push the boundaries of what is possible in DNA synthesis, ensuring that our technology not only meets current scientific needs but also opens the door to future discoveries. This funding round represents more than just a financial milestone—it reinforces our belief in the transformative impact of nature-inspired DNA manufacturing on science, medicine, and industry. With renewed vigor and a reinforced mission, Molecular Assemblies, Inc. is excited to lead the charge in powering the next generation of DNA-based products and technologies worldwide.
